Epigenetic strategies to boost CAR T cell therapy

Mol Ther. 2021 Sep 1;29(9):2640-2659. doi: 10.1016/j.ymthe.2021.08.003. Epub 2021 Aug 6.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has led to a paradigm shift in cancer immunotherapy, but still several obstacles limit CAR T cell efficacy in cancers. Advances in high-throughput technologies revealed new insights into the role that epigenetic reprogramming plays in T cells. Mechanistic studies as well as comprehensive epigenome maps revealed an important role for epigenetic remodeling in T cell differentiation. These modifications shape the overall immune response through alterations in T cell phenotype and function. Here, we outline how epigenetic modifications in CAR T cells can overcome barriers limiting CAR T cell effectiveness, particularly in immunosuppressive tumor microenvironments. We also offer our perspective on how selected epigenetic modifications can boost CAR T cells to ultimately improve the efficacy of CAR T cell therapy.

Keywords: antigen heterogeneity; chimeric antigen receptor T cells; combination therapy; epigenetics; exhaustion; infiltration; memory formation; metabolism; persistence; tumor microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Cell Differentiation
  • Combined Modality Therapy
  • Epigenesis, Genetic*
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Lymphocyte Activation
  • Neoplasms / genetics
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Receptors, Chimeric Antigen / metabolism
  • Tumor Microenvironment

Substances

  • Receptors, Chimeric Antigen